Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
43°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bluebird Bio
(NQ:
BLUE
)
0.5127
+0.0070 (+1.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bluebird Bio
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Peeling Back The Layers: Exploring bluebird bio Through Analyst Insights
March 27, 2024
Via
Benzinga
BLUE LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation – BLUE
March 27, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
March 26, 2024
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click...
Via
NewMediaWire
Kaplan Fox & Kilsheimer LLP Investigates bluebird bio, Inc. (NASDAQ: BLUE)
March 26, 2024
NEW YORK, NY - (NewMediaWire) - March 26, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased bluebird bio, Inc. (NASDAQ: BLUE) securities. Click...
Via
TheNewswire.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 26, 2024
Via
Benzinga
Peering Into bluebird bio's Recent Short Interest
March 22, 2024
Via
Benzinga
Is Bluebird Bio Stock a Buy Now?
March 13, 2024
Are you feeling brave?
Via
The Motley Fool
Forecasting The Future: 6 Analyst Projections For bluebird bio
March 05, 2024
Via
Benzinga
bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
March 26, 2024
From
bluebird bio, Inc.
Via
Business Wire
Earnings Scheduled For March 26, 2024
March 26, 2024
Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
Via
Benzinga
bluebird bio to Host Fourth Quarter and 2023 Annual Results Conference Call
March 25, 2024
From
bluebird bio, Inc.
Via
Business Wire
(BLUE) - Analyzing bluebird bio's Short Interest
February 29, 2024
Via
Benzinga
Why Bluebird Bio Stock Flew Higher Than the Market Today
March 18, 2024
The company was thrown a financial lifeline.
Via
The Motley Fool
bluebird bio Secures up to $175 Million Debt Financing with Hercules Capital
March 18, 2024
From
bluebird bio, Inc.
Via
Business Wire
bluebird bio Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
March 11, 2024
From
bluebird bio, Inc.
Via
Business Wire
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
March 06, 2024
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place
Via
MarketBeat
Why Bluebird Bio Stock Dived Into the Red on Tuesday
March 05, 2024
The biotech has had a tough time of it over the past few years; a pundit's revised take on the company won't improve that situation.
Via
The Motley Fool
MarketBeat Week in Review – 2/26 - 3/1
March 02, 2024
As the calendar turns to March, investors continue to climb the wall of worry, but with the S&P 500 at 5,000, the MarketBeat team helps show you where to invest
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
bluebird bio Stock Signals Potential to be a Multi-bagger
February 29, 2024
Driving a bargain of a short squeeze play, Bluebird Bio stock could soon announce what every investor is hoping to hear, here's what management could do
Via
MarketBeat
Topics
Economy
Exposures
Economy
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
February 27, 2024
Both companies are working on treatments for genetic disorders.
Via
Investor's Business Daily
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 29, 2024
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.
Via
Benzinga
bluebird bio: How to play LEAPS options for growth and income
February 27, 2024
Gene-editing is making huge headlines in the medical sector stemming from the first FDA approval for a CRISPR/cas9 treatment for sickle cell disease SCD and TDT
Via
MarketBeat
Exposures
Product Safety
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via
Benzinga
bluebird bio stock is ripe for a 400% institutional short squeeze
February 27, 2024
Bluebird Bio stock could be on the verge of a 400% pop on earnings, management has set the writing on the wall for institutional buying to trickle in
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Is CRISPR Therapeutics the NVIDIA of gene editing?
February 26, 2024
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Gene therapy: Why does it cost millions for a single treatment?
February 15, 2024
Gene therapy treatments have been making major headlines as advances in gene editing have gone mainstream thanks to the advent of CRISPR/Cas-9 technology.
Via
MarketBeat
Exposures
Product Safety
If You Invested $1,000 in Bluebird Bio in 2019, This Is How Much You Would Have Today
January 27, 2024
The answer hardly inspires confidence.
Via
The Motley Fool
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
January 17, 2024
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the...
Via
Benzinga
Exposures
Product Safety
2 Red Flags for Bluebird Bio Stock
January 10, 2024
The biotech's struggles may continue.
Via
The Motley Fool
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
...
21
22
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.